Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing ...

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) Friday said the National Medical Products Administration (NMPA) in China has ...

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...

With asthma and chronic obstructive pulmonary disease (COPD) on the rise, worsened by air pollution, tobacco use, and ...

On Friday, the FDA approved Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) ...

This is particularly concerning ... People with chronic liver disease (CLD) have a higher likelihood of barriers to health care, according to a study recently published in Gastro Hep Advances.

Discover how sugar modifications, particularly sialic acid, impact mucus formation and transport, contributing to diseases ...

Dublin, Sept. 13, 2024 (GLOBE NEWSWIRE) -- The "Chronic Obstructive Pulmonary Disease (COPD): Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering. In the 7MM ...

The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...

GlobalData’s latest report, ‘Chronic Obstructive Pulmonary Disease – Epidemiology Forecast to 2033’, reveals that the US will have the highest number of diagnosed prevalent cases of ...

Chronic obstructive pulmonary disease (COPD) is a disease of the respiratory tract that is characterized narrowing of the small airways and destruction of lung tissue. This leads to poor airflow ...